Thermo Fisher Scientific Raises Full-Year Guidance Following Strong Q3 Demand
Thermo Fisher Scientific (TMO) raised its full-year organic revenue growth guidance to 4% during its third quarter 2026 earnings call. The upward revision is driven by increased demand across biopharmaceutical customer channels and accelerating research funding, which has bolstered order volumes in core markets. The company is focusing on technological integration and strategic expansion to drive long-term value. This includes embedding artificial intelligence into scientific hardware to reduce manual setup times by approximately 90% and leveraging the Clario acquisition to expand clinical development capabilities through revenue synergies.
Tickers: $TMO
Topics: artificial intelligence biotechnology earnings call revenue guidance strategic acquisitions